» Articles » PMID: 27858714

Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome

Overview
Publisher Sage Publications
Specialties Geriatrics
Neurology
Date 2016 Nov 19
PMID 27858714
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Alzheimer's disease (AD) is the main medical problem in older adults with Down syndrome (DS). Studies of cerebrospinal fluid (CSF) AD biomarkers are limited and the feasibility of lumbar puncture (LP) is controversial in this population.

Objective: To analyze the frequency of complications after a LP in DS.

Methods: We collected data from 80 adults with DS that underwent a LP within the Down Alzheimer Barcelona Neuroimaging Initiative. Demographics, cognitive status, headache history, and presence of complications after the LP were recorded in every subject. In 53 of them (active group), this information was collected following a semi-structured and validated protocol that actively looks for complications. Other variables related to the LP procedure were also recorded. A telephone interview to the caregiver was performed 5-7 days after the procedure to ask about complications. Data from 27 subjects (clinical practice group), from whom the presence of complications was obtained in a medical follow-up visit within the three months after the LP, were also included.

Results: There were no adverse events in 90% of our participants. The most frequent complication was headache (6.25%); only one subject reported a typical post-lumbar puncture headache with moderate severity that required analgesic treatment. Dizziness (3.75%) and back pain (1.25%) were also reported. All the participants that reported complications belonged to the active group.

Conclusion: LP can be safely performed to study CSF biomarkers in DS. The reported complications are qualitatively similar to the general population, but are less frequently reported, even when actively searched for.

Citing Articles

Exploring peripheral fluid biomarkers for early detection of Alzheimer's disease in Down syndrome: A literature review.

Jacob C, Tollenaere M, Kachar H, Potier M, De Deyn P, Van Dam D Heliyon. 2025; 11(1):e41445.

PMID: 39850411 PMC: 11755057. DOI: 10.1016/j.heliyon.2024.e41445.


Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome.

Carmona-Iragui M, OConnor A, Llibre-Guerra J, Lao P, Ashton N, Fortea J EBioMedicine. 2024; 108:105327.

PMID: 39366843 PMC: 11663788. DOI: 10.1016/j.ebiom.2024.105327.


Characterization of white matter hyperintensities in Down syndrome.

Morcillo-Nieto A, Zsadanyi S, Arriola-Infante J, Carmona-Iragui M, Montal V, Pegueroles J Alzheimers Dement. 2024; 20(9):6527-6541.

PMID: 39087352 PMC: 11497714. DOI: 10.1002/alz.14146.


Down Syndrome-Basque Alzheimer Initiative (DS-BAI): Clinic-Biological Cohort.

Altuna M, Estanga A, Garrido A, Saldias J, Canada M, Echeverria M J Clin Med. 2024; 13(4).

PMID: 38398452 PMC: 10889106. DOI: 10.3390/jcm13041139.


Voxel-based dysconnectomic brain morphometry with computed tomography in Down syndrome.

Sanchez-Moreno B, Zhang L, Mateo G, Moldenhauer F, Brudfors M, Ashburner J Ann Clin Transl Neurol. 2023; 11(1):143-155.

PMID: 38158639 PMC: 10791030. DOI: 10.1002/acn3.51940.